Recce
Targeting Superbugs

recce.com.au
ACN 124 849 065

ASX ANNOUNCEMENT

5 January 2016

Recce Patent Family Confirmation

Australian early-stage pharmaceutical company, Recce Ltd (ASX: RCE), confirms (as required) the following statements:

1. P.R China Patent - Allowed Status

P.R. China Application 200880124515.5 has been allowed and fees paid by the Company such that grant is anticipated to be completed shortly. In view of P.R. China Application 200880124515.5 being allowed, a decision is now pending on whether or not to continue with P.R. China Application 201410136135.0 (Divisional).

2. Provisional Applications of Family 2 - Submitted

Further, Recce confirms the provisional applications to maintain the priority benefit of the applications the subject of Family 2 "Copolymer and Method for Treatment of Parenteral Infection" were submitted by the due date of 18 November 2015.

For further information please visit www.recce.com.au or contact:

Investor Relations
Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication
Karen Oswald – karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce, led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE antibiotics have been synthesised by an extremely simple and economic method.

RECCE antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both manufacturing of RECCE antibiotics, and the pre-clinical regulatory requirements - that should drive significant value for the Company.